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Introduction
Sub-Saharan Africa is disproportionately affected by the twin 
epidemics of HIV infection and chronic undernutrition, and a low 
body mass index (BMI) at the time of antiretroviral (ART) initiation 
is associated with increased early morbidity and mortality in HIV 
patients. In the first 90-180 days of ART, the mortality rate among 
undernourished HIV-infected adults is over 25% in some settings, 
which is 4 to 6-fold higher than HIV-infected adults with normal 
BMI and is independent of CD4 T-cell suppression [1-4]. While the 
etiology of the high early mortality is likely multifactorial, persistent, 
heightened systemic inflammation is a major risk factor for death in 
undernourished, HIV-infected adults starting ART in the region [5,6].
In individuals with normal BMI and without HIV, increased 
systemic inflammation is known to correlate with reduced heart rate 
variability, increased cardiovascular event rates, increased carotid 
intima-media thickness, coronary artery calcification, ischemic and 
dilated cardiomyopathies, myocardial infarction, and stroke [7-
11]. We hypothesized that a similar link between inflammation and 
cardiovascular dysfunction, possibly compounded by undernutrition-
related factors such as reduced muscle mass and bioavailable phosphate 
stores, is present in malnourished, HIV-infected adults in sub-Saharan 
Africa and may contribute to the high rate of early ART mortality 
in these patients [12-16]. To investigate this question further, we 
conducted a prospective pilot study to assess relationships between 
circulating inflammatory markers and cardiovascular function among 
Abstract
Introduction: Persistent systemic inflammation is associated with mortality among undernourished, HIV-infected 
adults starting antiretroviral therapy (ART) in sub-Saharan Africa, but the etiology of these deaths is not well understood. 
We hypothesized that greater systemic inflammation is accompanied by cardiovascular dysfunction over the first 12 
weeks of ART.
Methods: In a prospective cohort of 33 undernourished (body mass index <18.5 kg/m2) Zambian adults starting 
ART, we measured C-reactive protein (CRP), tumor necrosis factor-α receptor 1 (TNF-α R1), and soluble CD163 and 
CD14 at baseline and 12 weeks. An EndoPAT device measured the reactive hyperemia index (LnRHI; a measure 
of endothelial responsiveness), peripheral augmentation index (AI; a measure of arterial stiffness), and heart rate 
variability (HRV; a general marker of autonomic tone and cardiovascular health) at the same time points. We assessed 
paired changes in inflammation and cardiovascular parameters, and relationships independent of time point (adjusted 
for age, sex, and CD4+ T-cell count) using linear mixed models.
Results: Serum CRP decreased (median change -3.5 mg/l, p=0.02), as did TNF-α R1 (-0.31 ng/ml, p<0.01), over 
the first 12 weeks of ART. A reduction in TNF-α R1 over 12 weeks was associated with an increase in LnRHI (p=0.03), 
and a similar inverse relationship was observed for  CRP and LnRHI (p=0.07). AI increased in the cohort as a whole 
over 12 weeks, and a reduction in sCD163 was associated with a rise in the AI score (p=0.04). In the pooled analysis of 
baseline and 12 week data, high CRP was associated with lower HRV parameters (RMSSD, p=0.01; triangular index, 
p<0.01), and higher TNF-α R1 accompanied lower HRV (RMSSD, p=0.07; triangular index, p=0.06).
Conclusions: Persistent inflammation was associated with impaired cardiovascular health over the first 12 weeks 
of HIV treatment among undernourished adults in Africa, suggesting cardiac events may contribute to high mortality 
in this population.
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undernourished adults with advanced HIV over the first 12 weeks of 
ART.
Methods
The Mechanisms of Early Mortality in Adults Initiating Antiretroviral 
Therapy (MEMART) study was nested within the Nutritional Support 
for African Adults Starting Antiretroviral Therapy (NUSTART) study, 
which was a prospective, double-blinded, randomized placebo-
controlled clinical trial designed to test whether the addition of vitamins 
and minerals to a lipid-based nutritional supplement would reduce 
early mortality in ART-eligible, undernourished, HIV-infected patients 
(trial registration #PACTR201106000300631). The NUSTART study 
was conducted in Zambia and Tanzania from 2011 to 2013, and the 
MEMART pilot study prospectively enrolled a convenience sample of 
Zambian participants between August and December 2012 to evaluate 
the relationship between systemic inflammation and cardiovascular 
function.
Potentially eligible participants were evaluated by study staff at 
local health clinics and referred to University Teaching Hospital in 
Lusaka, Zambia for enrollment in the parent NUSTART trial and all 
study procedures. Inclusion criteria were a BMI <18.5 kg/m2, at least 
18 years of age, ART- naïve (except for prior receipt of short-term 
Prevention of Mother To Child Transmission regimens), ART-eligible 
as determined by CD4+ T-cell count <350 cells/µl or Stage 3 or 4 HIV 
disease, willing to undertake intensive ART follow-up in the study 
clinic, and able to provide written or thumb print informed consent. 
Exclusion criteria were participation in a potentially conflicting 
research protocol, pregnancy by self-report, or the presence of an acute 
infectious condition aside from tuberculosis (participants with known 
tuberculosis needed to be on treatment) or oral candidiasis as assessed 
by study clinicians. All participants received efavirenz, tenofovir, and 
emtricitabine as a first-line ART regimen.
At baseline (prior to ART initation) and 12 weeks after ART 
initiation, measurements of systemic inflammation and oxidative 
stress were obtained. The inflammatory markers C-reactive protein 
(CRP), soluble CD163, and tumor necrosis factor-α receptor 1 
(TNF-α R1, a soluble receptor of TNF-α that changes in relation to the 
circulating cytokine level) were measured using ELISA (R&D Systems, 
Minneapolis, MN USA). Soluble CD14 was also measured using ELISA 
(Hycult Biotech, Uden, Netherlands). Urine samples were collected for 
assessment of oxidative stress using the 15-F2t-isoprostane/creatinine 
ratio (Oxford Biomedical Research, Rochester Hills, MI). 
Cardiovascular assessments at baseline and after 12 weeks of ART 
included seated blood pressure and heart rate, ECGs to measure the 
corrected QT interval, and EndoPAT (Itamar Medical, Caesarea, 
Israel) assessment of the reactive hyperemia index (LnRHI; natural-
log transformed), peripheral augmentation index (AI), and heart rate 
variability (HRV, comprising the root mean square of the successive 
differences [RMSSD], triangular index, high and low frequency 
variation, and power ratio, which is the ratio of low-frequency to high-
frequency oscillations) [17]. The EndoPAT is a portable device to assess 
peripheral arteriolar tonography, or the reactivity of digital vessels 
in response to a brief period of ischemia (produced by inflation of a 
blood pressure cuff) [18]. A LnRHI value below ≤ 0.51 was previously 
shown to provides a sensitivity of 82% and a specificity of 77% for 
diagnosing coronary endothelial dysfunction in a large clinical study 
[18]. Higher AI values indicate increased arterial stiffness, as measured 
by the magnitude of the reflected arterial pressure wave during systole 
[19]. HRV, which was recorded for 5 minutes preceding brachial artery 
occlusion, is a measure of variations of both instantaneous heart rate 
and beat-to-beat intervals, and lower HRV is thought to reflect poor 
autonomic tone which confers increased risk of cardiovascular events 
and mortality [20,21]. 
Participant clinical and demographic characteristics were expressed 
as percentages or as median values with interquartile range. The change 
in each variable from recruitment to 12 weeks of ART was assessed using 
the Wilcoxon signed rank test. Our primary analysis evaluated whether 
changes in cardiovascular markers were associated with changes in 
inflammatory markers (i.e., within-patient paired comparison) using 
ordinary least squares regression, adjusted for the effect of baseline 
values. As a secondary analysis, we assessed the relationships between 
inflammatory biomarkers and cardiovascular markers irrespective of 
time point (baseline or 12 weeks) using a linear mixed model with a 
random effect for the patient to account for correlation that may arise 
from measurements taken from the same patient, adjusted for age, sex, 
and pre-treatment CD4+ T-cell count. Inflammatory markers were 
log-transformed, and cardiovascular markers remained on the unit 
scale (with the exception of LnRHI). Analyses were performed using 
R (version 2.12.1; www.r-project.org). Analysis scripts are posted at 
biostat.mc.vanderbilt.edu/ArchivedAnalyses. 
The funding source had no role in the study design, data collection, 
data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the study and 
had the responsibility for the decision to submit for publication.
Results
Sixty ART-naïve adults were recruited for this study and 33 returned 
at 12 weeks for the clinical assessment and laboratory studies. Of the 
27 patients without week 12 data, one-third (n=9) had never started 
ART, 3 died, 3 withdrew due to relocation, pregnancy, or injury (road 
traffic accident), and 12 declined to return for week 12 measurements. 
Among the 3 deceased patients, one died of encephalitis and sepsis, 
and the other two died at home of unknown causes. Those included 
and excluded from the analysis were similar in regards to age, sex, and 
pre-treatment BMI, serum hemoglobin, and CD4+ T cell count (p>0.05 
for all). Among the 33 patients in the analysis cohort, 58% were male, 
the median age was 36 years (interquartile range [IQR] 31-42 years), 
and the median CD4+ T cell count was 224 cells/µl (IQR 151-273 cells/
µl; Table 1). All participants were undernourished according to WHO 
criteria (i.e. BMI <18.5 kg/m2), with a median BMI of 16.7 kg/m2 (IQR 
15.4-17.6 kg/m2). Over twelve weeks of ART, the median weight gain 
was 2.5 kg (IQR 0.1-6.0 kg) and the median change in BMI was 0.9 kg/
m2 (0.0-1.9 kg/m2). Baseline median CRP level was markedly elevated 
at 18.3 mg/l and declined to 6.4 mg/l by week 12 (p=0.02), and TNF-α 
R1 declined from 1.3 to 1.0 ng/ml (p<0.01, Table 1 and Figure 1). 
In the linear model of paired changes (Table 2), the change in 
TNF-α R1 over 12 weeks was inversely associated with the LnRHI score 
(p=0.03), and a similar relationship was observed for CRP (p=0.07), 
indicating increased endothelial responsiveness as inflammation 
declined. The change in sCD163 over 12 weeks was also inversely 
associated with the change in the AI score (p=0.04), indicating increased 
arterial stiffness was present in those patients with greater reductions in 
sCD163. Lastly, a reduction in sCD163 and TNF-α R1 over 12 weeks 
was accompanied by a reduction in the resting heart rate (p=0.06 for 
both). No other changes in the inflammatory markers were significantly 
associated with changes in the cardiovascular markers.
The associations between inflammatory markers and cardiovascular 
markers also were assessed using linear mixed models pooling data from 
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both time points and adjusting for age, sex, and baseline CD4+ T-cell 
count (Table 3). While this method does not assess whether biomarkers 
change in conjunction with each other, it detects relationships between 
biomarkers that may persist over time. CRP was inversely associated 
with several measurements of HRV: RMSSD (p=0.01), triangular index 
(p<0.01), and high frequency variations (p=0.02). There was also an 
inverse relationship between TNF-α R1 and systolic (p=0.05) and 
diastolic blood pressure (p=0.05), RMSSD (p=0.07), and triangular 
index (p=0.06). However, TNF-α R1 was positively associated with 
LnRHI (p=0.01), which was unexpected given the directionality 
of relationships observed in the linear models of paired changes in 
inflammatory and cardiovascular variables. Higher heart rate was 
associated with higher CRP (p<0.01) and soluble CD14 levels (p<0.01). 
While there was a significant increase in the urine isoprostane/
creatinine ratio over 12 weeks, the ratio was not associated with any 
of the inflammatory biomarkers or with the cardiovascular parameters 
(data not shown). We did not detect any other significant relationships 
between inflammatory biomarkers and cardiovascular markers. 
Discussion
This pilot study examining relationships between inflammatory 
and cardiovascular markers in undernourished HIV-infected adults 
during initiation of ART demonstrated several novel findings that 
may implicate poor cardiovascular health and function as one of the 
mechanistic links in the well-described relationship between persistent 
inflammation and early mortality in this population. We found that 
higher levels of circulating inflammatory markers were associated with 
reduced vascular endothelial responsiveness and heart rate variability, 
both indicative of poor cardiovascular health, at baseline and after 12 
weeks of ART. However, we did not observe paired changes in several 
of these variables, which may have been due in part to our small cohort 
size. Based on these findings, further studies are warranted to assess 
the relationship between inflammation and cardiovascular health over 
time, and to assess whether cardiovascular dysfunction, particularly 
sudden cardiac death, is a frequent proximate cause of early mortality 
among malnourished adults starting ART. 
Serum CRP levels in our participants were high at baseline (median 
18.3 mg/l) and remained elevated, although reduced, at 12 weeks (6.4 
mg/l). While CRP levels over 3.0 mg/l have been associated with high 
cardiovascular risk in US and European studies of HIV-infected and 
uninfected adults, caution is warranted in extrapolating these findings 
to African HIV patients given differences in populations, background 
disease risk, and laboratory methodology [22]. During 6 years of 
observation, Triant et al. found that the odds of an acute myocardial 
infarction was more than four-fold higher for patients with both an 
elevated CRP and HIV compared to uninfected individuals with 
normal CRP [23]. During 29 months of observation, Duprez et al. 
similarly found that the odds of a cardiovascular event were two-fold 
Demographic and clinical characteristics
Female sex, n (%) 14 (42%)
Age (median years, IQR) 36 (31-42)
Baseline BMI (median kg/m2, IQR) 16.7 (15.4-17.6)
Week 12 BMI (median kg/m2, IQR) 17.6 (16.5-19.0)a 
Baseline CD4+ count (median cells/μl, IQR) 224 (151-273)
Week 12 CD4+ count (median cells/μl, IQR) 349 (275-426)a 
Median serum, urine, and cardiovascular values pre-treatment and after 12 weeks 
of antiretroviral therapy, median (IQR)
Variable Recruitment Week 12 of ART
C-reactive protein (mg/l) 18.3 (4.5-64.8) 6.4 (3.8-19.7)a
TNF-α receptor 1 (ng/ml) 1.3 (0.8-2.4) 1.0 (0.6–1.3)a
Soluble CD163 (ng/ml) 684 (511-1022) 531 (376-1040)
Soluble CD14 (µg/ml) 2.4 (2.1-2.7) 2.5 (2.0-3.1)
Isoprostane-to-creatinine ratio 0.02 (0.01-0.05) 0.09 (0.05-0.24)a
Augmentation Index 11.9 (1.0-30.0) 19.0 (0.1-25.9)
Reactive Hyperemia Index 0.6 (0.3-0.8) 0.6 (0.4-0.7)
QTc (ms) 434 (421-447) 431 (417-446)
RMSSD (ms) 26.4 (17.5-41.3) 37.2 (19.2-71.6)a
Triangular Index 6.8 (5.9-10.6) 9.6 (6.1-14.5)
Low frequency variations (ms2) 130.2 (85.0-151.9) 112.9 (76.1-151.6)
High frequency variations (ms2) 214.7 (154.7-260.8) 232.6 (169.7-327.1)
Power Ratio 0.6 (0.4-0.9) 0.4 (0.3-0.9)
Systolic blood pressure (mm Hg) 100 (93-110) 110 (100-120)a
Diastolic blood pressure (mm Hg) 60 (60-70) 70 (60-70)
Heart rate (bpm) 78 (71-89) 68 (63-82)
Abbreviation: BMI: Body Mass Index; QTC: Corrected QT interval; RMSSD: Root 
Mean Square of the Successive Differences; TNF-α: Tumor Necrosis Factor-α.
Reactive hyperemia index is natural log transformed
a: p<0.05 for change at 12 weeks
Table 1: Description of the cohort (n=33).
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C-reactive protein 0.00, p=0.96
-2.22, 
p=0.54
-0.09, 
p=0.07
1.35, 
p=0.74
-5.76, 
p=0.37
-1.32, 
p=0.18
5.60, 
p=0.65
-22.80, 
p=0.18
0.05, 
p=0.81
1.62, 
p=0.60
-0.09, 
p=0.97
3.43, 
p=0.23
Tumor necrosis factor-α 
receptor 1
-0.08, 
p=0.52
-6.22, 
p=0.54
-0.26, 
p=0.03
9.62, 
p=0.31
-10.09, 
p=0.69
-2.13, 
p=0.41
12.78, 
p=0.70
-38.72, 
p=0.40
0.02, 
p=0.97
0.20, 
p=0.98
-3.98, 
p=0.38
14.10, 
p=0.06
Soluble CD163 0.02, p=0.86
-14.06, 
p=0.04
-0.11, 
p=0.17
2.71, 
p=0.68
-2.05, 
p=0.91
-1.75, 
p=0.34
28.46, 
p=0.16
1.86 
p=0.95
0.33, 
p=0.23
5.19, 
p=0.30
2.34, 
p=0.46
9.44, 
p=0.06
Soluble CD14 -0.03, p=0.83
-15.37, 
p=0.25
-0.05, 
p=0.77
-4.08, 
p=0.73
11.25, 
p=0.76
0.41, 
p=0.91
9.91, 
p=0.79
-21.07, 
p=0.72
-0.03, 
p=0.96
-2.51, 
p=0.78
2.45, 
p=0.67
13.31, 
p=0.17
Models estimate the relationship between the change in log-transformed inflammation biomarker and change in cardiovascular marker using ordinary least squares 
regression, adjusted for baseline values.  Bold values represent statistically significant findings.
Abbreviation: QTC: Corrected QT interval; RMSSD: Root Mean Square of the Successive Differences.
Reactive hyperemia index is natural log transformed
Table 2: Linear models of the paired change in cardiovascular markers and inflammation biomarkers over 12 weeks of ART.
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higher in HIV patients with elevated CRP (mean CRP 3.3 mg/l) when 
compared to those with normal CRP (mean CRP 1.7 mg/l) [24]. One 
explanation for the high mortality rate among malnourished patients in 
the early post-ART period may be that increased metabolic activity and 
weight gain accompanying virologic suppression places sudden strain 
on a cardiovascular system already injured by the effects of advanced 
HIV disease and chronic inflammation. 
Increases in LnRHI, indicating improved arteriolar responsiveness 
following ischemia, were associated with reductions in circulating 
TNF-α R1 levels over 12 weeks, and a similar relationship with CRP 
levels approached significance (p=0.07). TNF-α is known to contribute 
to the pathogenesis of atherosclerosis, heart failure, and myocardial 
ischemia, and both CRP and TNF-α are associated with markedly 
elevated coronary artery calcium scores and carotid intima-media 
Cardiovascular markers (regression outcome)
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(log-transformed 
regression predictor) Is
op
ro
st
an
e-
to
-C
re
at
in
in
e 
ra
tio
A
ug
m
en
ta
tio
n 
In
de
x
R
ea
ct
iv
e 
H
yp
er
em
ia
 
In
de
x
Q
Tc
R
M
S
S
D
Tr
ia
ng
ul
ar
 
In
de
x
Lo
w
 
fre
qu
en
cy
 
va
ria
tio
ns
H
ig
h 
fre
qu
en
cy
 
va
ria
tio
ns
P
ow
er
 R
at
io
S
ys
to
lic
 b
lo
od
 
pr
es
su
re
D
ia
st
ol
ic
 
bl
oo
d 
pr
es
su
re
H
ea
rt 
ra
te
C-reactive protein 0.01, p=0.95
-1.36, 
p=0.06
0.02, 
p=0.37
-0.77, 
p=0.90
-7.03, 
p=0.01
-1.73, 
p<0.01
-0.32, 
p=0.86
-26.35, 
p=0.02
0.18, 
p=0.18
-2.51, 
p=0.28
-1.93, 
p=0.16
4.90, 
p<0.01
Tumor necrosis factor-α 
receptor 1
-0.07, 
p=0.51
0.44, 
p=0.95
0.14, 
p=0.01
1.30, 
p=0.77
-17.83, 
p=0.07
-2.12, 
p=0.06
-12.02, 
p=0.34
-19.54, 
p=0.40
-0.04, 
p=0.96
-9.40, 
p=0.05
-5.12, 
p=0.05
7.70, 
p=0.11
Soluble CD163 -0.11, p=0.20
-6.01, 
p=0.40
-0.04, 
p=0.46
0.02, 
p=0.70
5.75, 
p=0.39
-0.79, 
p=0.60
11.60, 
p=0.23
-20.80, 
p=0.33
0.25, 
p=0.18
2.06, 
p=0.26
0.70, 
p=0.34
4.82, 
p=0.21
Soluble CD14 0.00, p=0.95
-13.88, 
p=0.10
-0.04, 
p=0.67
6.62, 
p=0.19
12.34, 
p=0.43
-1.70, 
p=0.46
-5.34, 
p=0.78
-46.00, 
p=0.24
0.19, 
p=0.58
-9.04, 
p=0.17
-5.53, 
p=0.11
15.52, 
p<0.01
Results from linear mixed models pooling data across both recruitment and 12 weeks of ART. Models adjusted for age, sex, and baseline CD4+ T-cell count and 
included a random effect for patient. Bold values represent statistically significant findings.
Abbreviation: QTC: Corrected QT interval; RMSSD: Root Mean Square of the Successive Differences
Reactive hyperemia index is natural log transformed
Table 3: Regression coefficients estimating the associations between cardiovascular markers and inflammation.
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Figure 1: Changes in inflammation biomarkers and cardiovascular parameters over 12 weeks of antiretroviral therapy.
Yellow lines represent paired samples and blue lines represent smoothed (loess) curves fit to the data. As in the statistical models, the inflammation biomarkers are 
log-transformed and the cardiovascular markers are on the unit scale. Wilcoxon signed rank test was used to assess statistical significance. 
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thickness, two surrogate markers of subclinical atherosclerosis [9,25]. 
Similarly, LnRHI is significantly associated with carotid intima-media 
thickness and with coronary artery disease, and it is an independent 
predictor of major adverse cardiac events [26-28]. The combination 
of elevated CRP or TNF-α with impaired endothelium-dependent 
vasodilation correlates with increased risk of cardiac events in patients 
with coronary artery disease, ischemic cardiomyopathy, nonischemic 
cardiomyopathy, post-cardiotomy heart failure, and cardiogenic shock 
[10,29-31]. However, in our pooled analysis, TNF-α R1 levels were 
positively associated with LnHRI, which was unexpected and may 
indicate a more complex relationship.
Heart rate varies with inputs from the autonomic nervous system; 
therefore, heart rate variability has been used to measure autonomic 
function [32]. In our cohort, higher CRP was significantly associated 
with reductions in several markers of HRV (RMSSD, triangular index, 
and high-frequency variations), and TNF-α R1 was closely related with 
two of these parameters (RMSSD and triangular index). Low HRV is 
known to be associated with disease severity in chronic coronary artery 
disease, heart failure, and atrial fibrillation, and with sudden cardiac 
death among patients with heart failure, atrial fibrillation, or recent 
myocardial infarction [33-37]. 
We observed divergent relationships between the inflammation 
markers and peripheral AI as compared to LnRHI. The median AI 
value increased in the cohort as a whole over 12 weeks, indicative of 
increasing arterial stiffness, and greater gains in AI were associated 
with larger reductions in circulating CD163 over the same period. A 
prior study of aortic inflammation in HIV-infected adults in the United 
States using positron emission tomography found greater aortic arterial 
inflammation was associated with higher circulating CD163 levels, and 
we had expected that ART initiation would result in reduced vascular 
monocyte activation and relaxation of the arteries [38]. However, two 
recent studies suggest that both systemic and vascular inflammation are 
not major determinants of arterial stiffness as measured by AI [39,40]. 
Furthermore, the median baseline peripheral AI value of 11.9 in our 
cohort was approximately half the mean value of 21.4 measured using the 
EndoPAT device in a cohort of healthy black Americans, and the increase 
in AI we observed may represent a return to a more normal physiologic 
state on ART rather than a pathologic stiffening of the vasculature related 
to cardiovascular disease [19]. The inverse CD163-AI relationship in 
our cohort may be a chance finding, and further studies are needed to 
investigate the etiology and consequences of low arterial stiffness in 
malnourished adults with HIV.
Lastly, there was a significant increase in the urine isoprostane/
creatinine ratio over 12 weeks, but the ratio was not associated with any 
of the inflammatory biomarkers or with the cardiovascular parameters. 
We attribute this rise in the peroxidation of essential fatty acids to 
increased free radicals resulting from accelerated metabolic activity on 
ART, which was not sufficient to exert a significant modulating effect on 
the already high levels of circulating inflammatory biomarkers [41]. On 
the other hand, the increase in the urine isoprostane/creatinine ratio 
could also be due to a reduction in the urine creatinine concentration, 
either because ART improved nitrogen retention or participants were 
less dehydrated at 12 weeks as compared to baseline.
Our pilot study was limited by small sample size and high levels 
of incomplete follow-up; the latter is common in Sub-Saharan African 
ART programs. Additionally, the study only included undernourished, 
HIV-infected adults and did not include normal-BMI controls, which 
precluded an assessment of whether our findings are specific only to 
undernourished  HIV-infected adults or more broadly characterize 
patients starting ART in Zambia. Lastly, as the goal of this pilot study 
was to explore potential links between inflammation and cardiovascular 
instability in a population not previously studied in detail, we 
performed a large number of statistical comparisons in an exploratory 
manner without adjusting for multiple comparisons. This may have led 
to chance findings, such as the conflicting relationships between TNF-α 
R1 and LnRHI, and our results need to be confirmed in a large cohort.
Conclusions
In this pilot study, higher circulating levels of systemic 
inflammatory biomarkers were associated with several indicators of 
impaired cardiovascular health in undernourished HIV-infected adults 
starting ART in Zambia. This may implicate disruptions in cardiac or 
vascular physiology as one of the causal links in the well-described 
relationship between persistent inflammation and early mortality in 
this population. At present there is a paucity of data on cardiovascular 
disease risk factors among HIV-infected individuals in sub-Saharan 
Africa. Our findings should be explored in a larger cohort to assess 
the mortality burden of cardiac events in the first months after starting 
HIV treatment, to examine underlying biological mechanisms, and to 
identify opportunities for therapeutic intervention.
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